ESGBERT/base_data · Datasets at Hugging Face

sentence stringlengths 1 23.5k ⌀
For three years, Teva has partnered with Mount Sinai’s Arnhold Institute for Global Health to design and implement novel programs for vulnerable patients with MCC, providing behavior change tools to help them better manage their own health.
I was given here and I travel with it.
Program participant Read more about the new published study by Mount Sinai researchers.
Amalia Adler-Waxman, Teva’s Vice President of ESG and Global Health, discussed MCC and the National Health Service (NHS) Long-Term Plan, including how integrated care systems and innovation can help patients take control of their well-being.
leader on NCD policy and practice, convener of the civil society movement and an advocate for people at risk of, or living with, NCDs.
or those available legally by prescription that are misused or subsequently diverted—is a public health crisis in the US and other countries around the world.
We recognize caregivers, whether they are parents, children, siblings, friends or neighbors, play an important role in patients’ health and well-being.
When we began to approach caregivers in a unified way, we didn’t truly understand the magnitude of caregiving.
Our global research, coupled with our market insights, revealed that nearly half of the global population consider themselves caregivers.
for and how the caregiver role has impacted their lives and their own health. 1 Teva Brand Research, 2020.
Contributing to Healthy Communities In countries: Canada, Israel, Ukraine, France, Chile, Argentina and Russia.
Contributing to Healthy Communities https://www.tevapharm.com/globalassets/tevapharm-vision-files/https://www.tevapharm.com/globalassets/tevapharm-vision-files/2019-global-patient-advocacy-disclosure.pdf As a global company that affects the health of millions of people, we have an immense responsibility—a responsibility to act ethically and with integrity and maintain accountability throughout our supply chain to ensure our medicines get to those who need them, safely and consistently.
Teva’s employees are the heart of our company.
In employees to ensure a healthy and safe workforce, implemented new programs that foster a diverse and inclusive culture and offered educational opportunities to promote growth and development.
Promoting diversity and inclusion At Teva, we pride ourselves on getting it done together.
to promote gender equality and prevent domestic violence.
We aim to create an empowering culture that recognizes and acknowledges our employees’ accomplishments.
Supporting health and well-being Through practical tools and local programs, we address the physical, financial, social and emotional needs of our employees and their families.
well-being and engagement and learn how we can support them and help them work to the best of their ability.
Teva is a member of the International Process Safety Group (IPSG) and the ORC HSE Strategies Occupational Safety and Health Network, through which we share and learn about occupational health and safety (OHS) best practices.
in total lost workdays Teva’s facility in Goa, India was awarded the Safety Excellence Award in Sustainability Awards, which recognize and honor efforts made by companies that actively integrate sustainability principles into their business culture.
It represents knowledge, wisdom and oversight of Teva’s business practices—helping to create accountability for compliance across the business.
Anti-trust training was also included in the Code of Conduct recertification.
Compliance and Ethics Our and transparent behavior across our business, because compliance is everyone’s responsibility.
of Conduct breaches to our Office of Business Integrity.
as outlined in our Policy on Clinical Trial Transparency & Disclosure.
manages activities including clinical trial registrations and results disclosures on ClinicalTrials.gov and the EU Clinical Trials Register for specialty products.
Conducting animal research responsibly For more than a century, Teva has been dedicated to developing medicines to improve people’s lives.
we work to continuously improve the impact of our manufacturing and daily operations on the environment.
we implement measures to avoid, reduce or control pollution and promote responsible and efficient use of energy and natural resources across our company and supply chain.
six hospitals in the UK, with hopes to expand the initiative and continue to reduce the environmental impact of inhalers.
of light and heat passing through the windows, which reduces energy consumption during summer — Has two stratified tanks that allow recovery of energy for cooling and heating systems — Uses 33 Teva 2019 ESG Progress Report \| Leading a Responsible Business https://letstalkrespiratory.com/about-teva/ Teva’s EHS Excellence Awards recognize initiatives across the company that drive sustained improvements in EHS systems, processes or performance and promote a safe and responsible culture.
We installed a biomass boiler at one of our sites in was only operating at 50% capacity.
In and installed steam piping to supply steam to our adjacent site.
This allowed us to decommission the heavy-fuel oil boiler, maximizing the efficiency of our existing boiler and using biofuel to generate steam across our site.
We were also able to avoid reduce running costs by $113,000.
Our Goa, India site also undertook a project to reduce waste, dispose of hazardous waste through environmentally-friendly and economical processes and convert waste to energy—with the goal of becoming a zero-to-landfill site.
Each year, the campus disposed of waste—70% through incineration and 30% through landfilling.
That changed in June we began transferring hazardous waste to the cement industry to be co-processed in a cement kiln, reducing the amount of fossil fuel used and CO2 emissions per ton of cement produced, avoiding the use of 120 tons of coal in 2018.
This solution supported GHG reductions and Teva’s waste reduction activities.
day, patient safety is prioritized across our business.
is made up of safety officers across about patients’ experiences with our products, including adverse events.
and the integral role each of us can play in improving patient safety.
In Nigeria, Teva supported a government to government capacity building seminar on patient safety and anticounterfeiting for senior staff of the Nigerian National Agency for Food and Drug Administration Control (NAFDAC), organized by the Israeli Embassy.
by the International Council for Harmonisation and Current Good Manufacturing Practices as stipulated by all major authorities like the US Food and Drug Administration (FDA), European Medicines Agency, UK’s Medicines and Healthcare Products Regulatory Agency, Japan’s Pharmaceuticals and Medical Devices Agency, China’s National Medical Products Administration and Russia’s Ministry of Health.
to follow documented procedures, methods and batch records or to operate within controlled conditions.
a possible deviation from the product specification (i.e., changes in, or deterioration of, the physical and/or chemical characteristics of the product or packaging).
on Human Rights Teva’s supply chain is an integral part of our company, helping us ensure our medicines reach the nearly 200 million patients who rely on them each day.
We operate the largest fully-integrated manufacturing and delivery network in the pharmaceutical industry, with (CMOs) that support development, manufacturing and packaging.
We hold each of our partners to the same standards we hold ourselves to and expect them to conduct business ethically, act with integrity and protect human rights.
In partnership with EcoVadis—the leading provider of sustainability risk and performance ratings for global supply chains—Amgen, Boehringer Ingelheim, GlaxoSmithKline and Takeda, Teva continues to be part of the Responsible Health Initiative (RHI).
In platform and tracked high-risk suppliers’ corrective actions.
and incorporates PSCI Principles into our Supplier Code of Conduct.
Manufacturing active pharmaceutical ingredients Medicines are made up of several ingredients, most important of which are active pharmaceutical ingredients (API)—the ingredients that produce the intended effects.
to healthy communities and lead a responsible business.
in relation to the information set out below and presented in Teva’s and Governance Progress Report (‘the Report’).
view of Teva’s materiality assessment process, in accordance with the stated reporting criteria.
— Interviews with management representatives responsible for preparing the content and leading the material topic areas and with relevant personnel to understand and evaluate the materiality assessment and processes used for determining and reporting the selected topics.
Scope of our assurance engagement Whether the Stakeholder Engagement’ section of the report presents, in all material respects, a complete and balanced view of Teva’s materiality assessment process in accordance with the reporting criteria.
Our conclusions Based on our activities, as described below, nothing has come to our attention to indicate that the the ‘Materiality Assessment and Stakeholder Engagement’ section of the Report does not present, in all material respects, a complete and balanced view of TEVA’s materiality assessment process, in accordance with the stated reporting criteria.
A review of external media reporting relating to TEVA to identify relevant sustainability issues in the reporting period.
Interviews with management representatives responsible for preparing the content and leading the material topic areas and with relevant personnel to understand and evaluate the materiality assessment and processes used for determining and reporting the selected topics.
During our assurance engagement, due to travel restrictions following the outbreak of COVID-this year’s assurance engagement.
Jennifer Iansen-Rogers Head of Corporate Assurance ERM Certification and Verification Services, London www.ermcvs.com Email: post@ermcvs.com ERM CVS is a member of the ERM Group.
ERM CVS and the staff that have undertaken work on this assurance exercise provide no consultancy related services to TEVA in any respect.
102-8 Information on employees GRI Content Index, pages 49-50 102-9 Supply chain 2019 ESG Progress Report, pages 37-38 102-10 Significant changes Teva completed our two-year restructuring plan in 2019.
We support the precautionary approach introduced by the United Nations in Principle Declaration on Environment and Development and act to protect against environmental degradation where full scientific certainty does not exist.
Teva has participated in the UN Global Compact since 2010 and in 2019, we reconfirmed our membership as a participant.
Composition of the highest governance body and its committees Proxy Statement for Teva's 2020 Annual Shareholder Meeting, page 15 for information on director independence, executive/non-executive, age, tenure and gender; pages 8-13 for other significant positions and commitments and qualifications for service; page 16 for competencies 102-23 Chair of the highest governance body Proxy Statement for Teva’s 2020 Annual Shareholder Meeting, page 17; Teva's non-executive chairman of the board is Dr. Sol Barer.
102-37 Stakeholders’ involvement in remuneration Proxy Statement for Teva’s 2020 Annual Shareholder Meeting, pages 26-27, "Shareholder Engagement"; voting results for 2019 102-38 Annual total compensation ratio Proxy Statement for Teva’s 2020 Annual Shareholder Meeting, page 71 102-40 List of stakeholder groups 2019 ESG Progress Report, page 51 102-41 Collective bargaining agreements We respect the right of our employees to organize or join associations, and bargain collectively, if they choose to do so.
102-43 Stakeholder engagement 2019 ESG Progress Report, page 51 102-44 Key topics and concerns raised 2019 ESG Progress Report, page 51 102-45 Entities included This report covers all Teva’s owned and operated facilities around the world.
102-50 Reporting period 2019 calendar year 102-51 Date of most recent report July 11, 2019 102-52 Reporting cycle We report on an annual basis.
Environmental Sustainability 306-3 Significant Spills We centrally track and monitor environmental incidents (spills and releases) across our operations and in 2019 experienced 20 reportable events, compared with 44 in 2018 and 206 in 2017.
This improvement was the result of a significant focus being placed on proactive prevention of spills and releases in all operations, but especially in our Teva api business unit that has the greatest risk of such occurrences.
None of the resulted in a material environmental impact, harm to individuals, or a significant fine or penalty.
In many countries, Teva offers beyond the minimum standard by law, and in some countries, even goes above market practice.
page 402-1 Minimum notice periods regarding operational changes With respect to significant operational changes that substantially affect employees, we comply with applicable local labor laws and regulations, commitments in employment contracts and collective bargaining agreements in our countries of operation, which may differ from country to country.
In 2020, we began a new materiality assessment, which is still in progress.
topics include: — Business Ethics, Anti-bribery and Anti-corruption — Access to Health and Medicines — Quality Manufacturing and Patient Safety — Pricing — Sustainable Supply Chain — Corporate Governance These are subject to change based on our internal prioritization and finalization of the materiality process.
Disclosures https://www.tevapharm.com/globalassets/tevapharm-vision-files/teva_material-topic-definitions_ 205-1: Operations assessed for risks related to corruption Teva’s monitoring program assesses compliance risk for all operations that have a touchpoint with either healthcare professionals or government officials.
procedures 100% of applicable employees received communications regarding Teva’s anti-corruption policies and procedures.
In 2019, the Office of Business Integrity (OBI) received 207 reports about alleged misconduct.
warranted an investigation and five of the 52 are still under active investigation.
MWH/employee 302-3: Energy intensity 54 Teva 2019 ESG Progress Report \| Disclosures 303-1: Interactions with water as a shared resource Access to clean and reliable water supplies is essential to Teva’s continued business.
The majority of water we consume at our manufacturing facilities is during active pharmaceutical ingredient (API) and medicine production, with a significant proportion of this associated with the utilities and auxiliary equipment needed to create the right production environments.
Most of the water from our facilities are discharged to municipal wastewater networks, with some of this water first receiving onsite treatment to meet wastewater quality parameters.
Efforts are currently being focused on performing water balances at these facilities to guide what steps can be taken to reduce our impact there.
these areas and build resilience into our business operations.
As part of our commitment to being a responsible steward of water, particularly in waterscarce areas, Teva made its first-ever (partial) CDP Water Security submission in 2019.
Teva always intends to conform to all applicable regulatory requirements, including those relating to any local, state, regional and national effluent discharge quality.
Going above and beyond regulatory requirements, as part of Teva’s PiE assessment program, including those related to AMR, where Teva identifies Predicted Environmental Concentrations (PEC) above those of the published Predicted No-Effect Concentration (PNEC), Teva will implement improvement measures to reduce discharge levels below the PNEC.
2017 and 2018 GHG emissions data have been restated following verification of our emissions for these two years, and adjusted for plant closures and divestments.
GHG data for these two years, therefore, represent verified GHG emissions for operations in line with their actual periods of activity during this period.
In without further action required, with five Notices of Violation received as a result of environmental inspections.
of employees is estimated based upon 2,000 hrs./yr.
• Teva follows Occupational Safety and Health Administration (OSHA) definitions for recordable injuries and illnesses.
• Occupational disease is defined as disease arising from an employee’s work situation or activity, specifically associated with the nature of the work, causing lost workdays or reassignment.
In certain cases, this Code of Conduct is supplemented by additional policies that cover specific topics in more detail or deal with certain local or regional issues.
The United Nations Global Compact (UNGC) is a strategic policy initiative that encourages companies around the world to adhere to human rights, labor standards, environmental protection and anti-corruption.
This Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.

For three years, Teva has partnered with Mount Sinai’s Arnhold Institute for Global Health to design and implement novel programs for vulnerable patients with MCC, providing behavior change tools to help them better manage their own health.

I was given here and I travel with it.

Program participant Read more about the new published study by Mount Sinai researchers.

Amalia Adler-Waxman, Teva’s Vice President of ESG and Global Health, discussed MCC and the National Health Service (NHS) Long-Term Plan, including how integrated care systems and innovation can help patients take control of their well-being.

leader on NCD policy and practice, convener of the civil society movement and an advocate for people at risk of, or living with, NCDs.

or those available legally by prescription that are misused or subsequently diverted—is a public health crisis in the US and other countries around the world.

We recognize caregivers, whether they are parents, children, siblings, friends or neighbors, play an important role in patients’ health and well-being.

When we began to approach caregivers in a unified way, we didn’t truly understand the magnitude of caregiving.

Our global research, coupled with our market insights, revealed that nearly half of the global population consider themselves caregivers.

for and how the caregiver role has impacted their lives and their own health. 1 Teva Brand Research, 2020.

Contributing to Healthy Communities In countries: Canada, Israel, Ukraine, France, Chile, Argentina and Russia.

Contributing to Healthy Communities https://www.tevapharm.com/globalassets/tevapharm-vision-files/https://www.tevapharm.com/globalassets/tevapharm-vision-files/2019-global-patient-advocacy-disclosure.pdf As a global company that affects the health of millions of people, we have an immense responsibility—a responsibility to act ethically and with integrity and maintain accountability throughout our supply chain to ensure our medicines get to those who need them, safely and consistently.

Teva’s employees are the heart of our company.

In employees to ensure a healthy and safe workforce, implemented new programs that foster a diverse and inclusive culture and offered educational opportunities to promote growth and development.

Promoting diversity and inclusion At Teva, we pride ourselves on getting it done together.

to promote gender equality and prevent domestic violence.

We aim to create an empowering culture that recognizes and acknowledges our employees’ accomplishments.

Supporting health and well-being Through practical tools and local programs, we address the physical, financial, social and emotional needs of our employees and their families.

well-being and engagement and learn how we can support them and help them work to the best of their ability.

Teva is a member of the International Process Safety Group (IPSG) and the ORC HSE Strategies Occupational Safety and Health Network, through which we share and learn about occupational health and safety (OHS) best practices.

in total lost workdays Teva’s facility in Goa, India was awarded the Safety Excellence Award in Sustainability Awards, which recognize and honor efforts made by companies that actively integrate sustainability principles into their business culture.

It represents knowledge, wisdom and oversight of Teva’s business practices—helping to create accountability for compliance across the business.

Anti-trust training was also included in the Code of Conduct recertification.

Compliance and Ethics Our and transparent behavior across our business, because compliance is everyone’s responsibility.

of Conduct breaches to our Office of Business Integrity.

as outlined in our Policy on Clinical Trial Transparency & Disclosure.

manages activities including clinical trial registrations and results disclosures on ClinicalTrials.gov and the EU Clinical Trials Register for specialty products.

Conducting animal research responsibly For more than a century, Teva has been dedicated to developing medicines to improve people’s lives.

we work to continuously improve the impact of our manufacturing and daily operations on the environment.

we implement measures to avoid, reduce or control pollution and promote responsible and efficient use of energy and natural resources across our company and supply chain.

six hospitals in the UK, with hopes to expand the initiative and continue to reduce the environmental impact of inhalers.

of light and heat passing through the windows, which reduces energy consumption during summer — Has two stratified tanks that allow recovery of energy for cooling and heating systems — Uses 33 Teva 2019 ESG Progress Report | Leading a Responsible Business https://letstalkrespiratory.com/about-teva/ Teva’s EHS Excellence Awards recognize initiatives across the company that drive sustained improvements in EHS systems, processes or performance and promote a safe and responsible culture.

We installed a biomass boiler at one of our sites in was only operating at 50% capacity.

In and installed steam piping to supply steam to our adjacent site.

This allowed us to decommission the heavy-fuel oil boiler, maximizing the efficiency of our existing boiler and using biofuel to generate steam across our site.

We were also able to avoid reduce running costs by $113,000.

Our Goa, India site also undertook a project to reduce waste, dispose of hazardous waste through environmentally-friendly and economical processes and convert waste to energy—with the goal of becoming a zero-to-landfill site.

Each year, the campus disposed of waste—70% through incineration and 30% through landfilling.

That changed in June we began transferring hazardous waste to the cement industry to be co-processed in a cement kiln, reducing the amount of fossil fuel used and CO2 emissions per ton of cement produced, avoiding the use of 120 tons of coal in 2018.

This solution supported GHG reductions and Teva’s waste reduction activities.

day, patient safety is prioritized across our business.

is made up of safety officers across about patients’ experiences with our products, including adverse events.

and the integral role each of us can play in improving patient safety.

In Nigeria, Teva supported a government to government capacity building seminar on patient safety and anticounterfeiting for senior staff of the Nigerian National Agency for Food and Drug Administration Control (NAFDAC), organized by the Israeli Embassy.

by the International Council for Harmonisation and Current Good Manufacturing Practices as stipulated by all major authorities like the US Food and Drug Administration (FDA), European Medicines Agency, UK’s Medicines and Healthcare Products Regulatory Agency, Japan’s Pharmaceuticals and Medical Devices Agency, China’s National Medical Products Administration and Russia’s Ministry of Health.

to follow documented procedures, methods and batch records or to operate within controlled conditions.

a possible deviation from the product specification (i.e., changes in, or deterioration of, the physical and/or chemical characteristics of the product or packaging).

on Human Rights Teva’s supply chain is an integral part of our company, helping us ensure our medicines reach the nearly 200 million patients who rely on them each day.

We operate the largest fully-integrated manufacturing and delivery network in the pharmaceutical industry, with (CMOs) that support development, manufacturing and packaging.

We hold each of our partners to the same standards we hold ourselves to and expect them to conduct business ethically, act with integrity and protect human rights.

In partnership with EcoVadis—the leading provider of sustainability risk and performance ratings for global supply chains—Amgen, Boehringer Ingelheim, GlaxoSmithKline and Takeda, Teva continues to be part of the Responsible Health Initiative (RHI).

In platform and tracked high-risk suppliers’ corrective actions.

and incorporates PSCI Principles into our Supplier Code of Conduct.

Manufacturing active pharmaceutical ingredients Medicines are made up of several ingredients, most important of which are active pharmaceutical ingredients (API)—the ingredients that produce the intended effects.

to healthy communities and lead a responsible business.

in relation to the information set out below and presented in Teva’s and Governance Progress Report (‘the Report’).

view of Teva’s materiality assessment process, in accordance with the stated reporting criteria.

— Interviews with management representatives responsible for preparing the content and leading the material topic areas and with relevant personnel to understand and evaluate the materiality assessment and processes used for determining and reporting the selected topics.

Scope of our assurance engagement Whether the Stakeholder Engagement’ section of the report presents, in all material respects, a complete and balanced view of Teva’s materiality assessment process in accordance with the reporting criteria.

Our conclusions Based on our activities, as described below, nothing has come to our attention to indicate that the the ‘Materiality Assessment and Stakeholder Engagement’ section of the Report does not present, in all material respects, a complete and balanced view of TEVA’s materiality assessment process, in accordance with the stated reporting criteria.

A review of external media reporting relating to TEVA to identify relevant sustainability issues in the reporting period.

Interviews with management representatives responsible for preparing the content and leading the material topic areas and with relevant personnel to understand and evaluate the materiality assessment and processes used for determining and reporting the selected topics.

During our assurance engagement, due to travel restrictions following the outbreak of COVID-this year’s assurance engagement.

Jennifer Iansen-Rogers Head of Corporate Assurance ERM Certification and Verification Services, London www.ermcvs.com Email: post@ermcvs.com ERM CVS is a member of the ERM Group.

ERM CVS and the staff that have undertaken work on this assurance exercise provide no consultancy related services to TEVA in any respect.

102-8 Information on employees GRI Content Index, pages 49-50 102-9 Supply chain 2019 ESG Progress Report, pages 37-38 102-10 Significant changes Teva completed our two-year restructuring plan in 2019.

We support the precautionary approach introduced by the United Nations in Principle Declaration on Environment and Development and act to protect against environmental degradation where full scientific certainty does not exist.

Teva has participated in the UN Global Compact since 2010 and in 2019, we reconfirmed our membership as a participant.

Composition of the highest governance body and its committees Proxy Statement for Teva's 2020 Annual Shareholder Meeting, page 15 for information on director independence, executive/non-executive, age, tenure and gender; pages 8-13 for other significant positions and commitments and qualifications for service; page 16 for competencies 102-23 Chair of the highest governance body Proxy Statement for Teva’s 2020 Annual Shareholder Meeting, page 17; Teva's non-executive chairman of the board is Dr. Sol Barer.

102-37 Stakeholders’ involvement in remuneration Proxy Statement for Teva’s 2020 Annual Shareholder Meeting, pages 26-27, "Shareholder Engagement"; voting results for 2019 102-38 Annual total compensation ratio Proxy Statement for Teva’s 2020 Annual Shareholder Meeting, page 71 102-40 List of stakeholder groups 2019 ESG Progress Report, page 51 102-41 Collective bargaining agreements We respect the right of our employees to organize or join associations, and bargain collectively, if they choose to do so.

102-43 Stakeholder engagement 2019 ESG Progress Report, page 51 102-44 Key topics and concerns raised 2019 ESG Progress Report, page 51 102-45 Entities included This report covers all Teva’s owned and operated facilities around the world.

102-50 Reporting period 2019 calendar year 102-51 Date of most recent report July 11, 2019 102-52 Reporting cycle We report on an annual basis.

Environmental Sustainability 306-3 Significant Spills We centrally track and monitor environmental incidents (spills and releases) across our operations and in 2019 experienced 20 reportable events, compared with 44 in 2018 and 206 in 2017.

This improvement was the result of a significant focus being placed on proactive prevention of spills and releases in all operations, but especially in our Teva api business unit that has the greatest risk of such occurrences.

None of the resulted in a material environmental impact, harm to individuals, or a significant fine or penalty.

In many countries, Teva offers beyond the minimum standard by law, and in some countries, even goes above market practice.

page 402-1 Minimum notice periods regarding operational changes With respect to significant operational changes that substantially affect employees, we comply with applicable local labor laws and regulations, commitments in employment contracts and collective bargaining agreements in our countries of operation, which may differ from country to country.

In 2020, we began a new materiality assessment, which is still in progress.

topics include: — Business Ethics, Anti-bribery and Anti-corruption — Access to Health and Medicines — Quality Manufacturing and Patient Safety — Pricing — Sustainable Supply Chain — Corporate Governance These are subject to change based on our internal prioritization and finalization of the materiality process.

Disclosures https://www.tevapharm.com/globalassets/tevapharm-vision-files/teva_material-topic-definitions_ 205-1: Operations assessed for risks related to corruption Teva’s monitoring program assesses compliance risk for all operations that have a touchpoint with either healthcare professionals or government officials.

procedures 100% of applicable employees received communications regarding Teva’s anti-corruption policies and procedures.

In 2019, the Office of Business Integrity (OBI) received 207 reports about alleged misconduct.

warranted an investigation and five of the 52 are still under active investigation.

MWH/employee 302-3: Energy intensity 54 Teva 2019 ESG Progress Report | Disclosures 303-1: Interactions with water as a shared resource Access to clean and reliable water supplies is essential to Teva’s continued business.

The majority of water we consume at our manufacturing facilities is during active pharmaceutical ingredient (API) and medicine production, with a significant proportion of this associated with the utilities and auxiliary equipment needed to create the right production environments.

Most of the water from our facilities are discharged to municipal wastewater networks, with some of this water first receiving onsite treatment to meet wastewater quality parameters.

Efforts are currently being focused on performing water balances at these facilities to guide what steps can be taken to reduce our impact there.

these areas and build resilience into our business operations.

As part of our commitment to being a responsible steward of water, particularly in waterscarce areas, Teva made its first-ever (partial) CDP Water Security submission in 2019.

Teva always intends to conform to all applicable regulatory requirements, including those relating to any local, state, regional and national effluent discharge quality.

Going above and beyond regulatory requirements, as part of Teva’s PiE assessment program, including those related to AMR, where Teva identifies Predicted Environmental Concentrations (PEC) above those of the published Predicted No-Effect Concentration (PNEC), Teva will implement improvement measures to reduce discharge levels below the PNEC.

2017 and 2018 GHG emissions data have been restated following verification of our emissions for these two years, and adjusted for plant closures and divestments.

GHG data for these two years, therefore, represent verified GHG emissions for operations in line with their actual periods of activity during this period.

In without further action required, with five Notices of Violation received as a result of environmental inspections.

of employees is estimated based upon 2,000 hrs./yr.

• Teva follows Occupational Safety and Health Administration (OSHA) definitions for recordable injuries and illnesses.

• Occupational disease is defined as disease arising from an employee’s work situation or activity, specifically associated with the nature of the work, causing lost workdays or reassignment.

In certain cases, this Code of Conduct is supplemented by additional policies that cover specific topics in more detail or deal with certain local or regional issues.

The United Nations Global Compact (UNGC) is a strategic policy initiative that encourages companies around the world to adhere to human rights, labor standards, environmental protection and anti-corruption.

This Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.